Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AN-FUC is a sulfated polysaccharide, specifically a fucoidan, extracted from the North Atlantic brown algae *Ascophyllum nodosum*. It is primarily composed of fucose and xylose, with sulfate groups typically located at the C2 and C4 positions of the sugar residues. Preclinical research indicates that AN-FUC possesses significant anti-hyperlipidemic and antioxidant activities. In animal models of hyperlipidemia, administration of AN-FUC fractions (such as AFC-1 and AFC-2) has been shown to improve lipid profiles by reducing total cholesterol, triglycerides, and LDL-C, while also lowering blood glucose levels and enhancing the activity of lipoprotein-metabolism-related enzymes. Furthermore, AN-FUC helps maintain gut microbiota diversity and mitigates oxidative stress, suggesting potential applications as a therapeutic agent or nutraceutical for metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AN-FUC.